相似文献
1
Clinical Efficacy and Toxicity of Anti-EGFR Therapy in Common Cancers.
J Oncol. 2009;2009:567486. doi: 10.1155/2009/567486. Epub 2009 May 6.
2
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Biomaterials. 2013 Nov;34(34):8690-707. doi: 10.1016/j.biomaterials.2013.07.100. Epub 2013 Aug 13.
3
Current status of small-molecule tyrosine kinase inhibitors targeting epidermal growth factor receptor in colorectal cancer.
Clin Colorectal Cancer. 2005 Nov;5 Suppl 2:S62-70. doi: 10.3816/ccc.2005.s.009.
4
Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cancer Treat Rev. 2014 May;40(4):567-77. doi: 10.1016/j.ctrv.2013.10.002. Epub 2013 Oct 12.
5
Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
Cochrane Database Syst Rev. 2020 May 12;5(5):CD013238. doi: 10.1002/14651858.CD013238.pub2.
6
The ErbB/HER family of protein-tyrosine kinases and cancer.
Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20.
7
Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.
Drugs. 2000;60 Suppl 1:15-23; discussion 41-2. doi: 10.2165/00003495-200060001-00002.
8
Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients.
Cancer Treat Rev. 2013 Dec;39(8):839-50. doi: 10.1016/j.ctrv.2013.05.001. Epub 2013 Jun 12.
9
Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
Curr Med Chem. 2009;16(29):3797-804. doi: 10.2174/092986709789177984.
10
Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Drugs Today (Barc). 2005 Feb;41(2):107-27. doi: 10.1358/dot.2005.41.2.882662.
引用本文的文献
1
Management and Mechanisms of Diarrhea Induced by Tyrosine Kinase Inhibitors in Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer.
Cancer Control. 2024 Jan-Dec;31:10732748241278039. doi: 10.1177/10732748241278039.
2
Facial Papulopustular Eruption during the COVID-19 Pandemic in Patients Treated with EGFR Inhibitors.
Dermatol Res Pract. 2024 Jan 11;2024:8859032. doi: 10.1155/2024/8859032. eCollection 2024.
3
Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins.
Breast Cancer (Dove Med Press). 2023 Jan 17;15:11-24. doi: 10.2147/BCTT.S390017. eCollection 2023.
4
Safety profile of tyrosine kinase inhibitors used in non-small-cell lung cancer: An analysis from the Italian pharmacovigilance database.
Front Oncol. 2022 Nov 23;12:1005626. doi: 10.3389/fonc.2022.1005626. eCollection 2022.
5
In silico design of EGFR inhibitors via 3D-QSAR, molecular docking, ADMET properties and molecular dynamics simulations.
Heliyon. 2022 Nov 14;8(11):e11537. doi: 10.1016/j.heliyon.2022.e11537. eCollection 2022 Nov.
6
Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists.
Cells. 2022 Sep 27;11(19):3007. doi: 10.3390/cells11193007.
7
Beyond HER2: Targeting the ErbB receptor family in breast cancer.
Cancer Treat Rev. 2022 Sep;109:102436. doi: 10.1016/j.ctrv.2022.102436. Epub 2022 Jul 15.
8
Renal Safety Profile of EGFR Targeted Therapies: A Study from VigiBase the WHO Global Database of Individual Case Safety Reports.
Cancers (Basel). 2021 Nov 24;13(23):5907. doi: 10.3390/cancers13235907.
9
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
10
Dermatologic Toxicities of Targeted Therapy and Immunotherapy in Head and Neck Cancers.
Front Oncol. 2021 May 27;11:605941. doi: 10.3389/fonc.2021.605941. eCollection 2021.
本文引用的文献
1
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy: subset analysis of Japanese patients.
Int J Clin Oncol. 2013 Aug;18(4):621-8. doi: 10.1007/s10147-012-0444-2. Epub 2012 Jul 19.
2
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
J Clin Oncol. 2008 Dec 1;26(34):5544-52. doi: 10.1200/JCO.2008.16.2578. Epub 2008 Oct 27.
3
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
4
Successful re-challenge with panitumumab in patients who developed hypersensitivity reactions to cetuximab: report of three cases and review of literature.
Cancer Chemother Pharmacol. 2009 May;63(6):1017-22. doi: 10.1007/s00280-008-0831-6. Epub 2008 Sep 10.
5
Fatal interstitial lung disease after erlotinib for non-small cell lung cancer.
J Thorac Oncol. 2008 Sep;3(9):1050-3. doi: 10.1097/JTO.0b013e318183a9f5.
6
Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial.
J Clin Oncol. 2008 Aug 1;26(22):3763-9. doi: 10.1200/JCO.2007.13.5145.
7
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
8
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy.
J Clin Oncol. 2008 Jul 10;26(20):3351-7. doi: 10.1200/JCO.2007.14.0111.
9
Phase II trial of sorafenib in advanced thyroid cancer.
J Clin Oncol. 2008 Oct 10;26(29):4714-9. doi: 10.1200/JCO.2008.16.3279. Epub 2008 Jun 9.
10
Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
Cancer. 2008 Jun 15;112(12):2749-55. doi: 10.1002/cncr.23490.
Zotero 插件